XYMOGEN Surpasses Seven Million Dollar Month Milestone

ORLANDO, Fla., Feb. 26, 2015 /PRNewswire/ -- Orlando-based health sciences company XYMOGEN has announced it has surpassed the Seven Million Dollar Month Revenue Milestone for January, 2015. This represents the third consecutive January in which the company surpassed a Million-Dollar Milestone, reaching $5 million and $6 million in 2013 and 2014, respectively. 

"This is a very promising start to 2015, and I don't see this dollar mark as a one-time occurrence," said XYMOGEN CEO Brian Blackburn. "With many initiatives in place as we launch 2015, I believe XYMOGEN will eclipse the $8 million mark in the third quarter of this year."

The company's revenues have been steadily increasing since their inception in 2003. Even at a time when few companies are growing, XYMOGEN has seen consistent sales growth for 44 consecutive quarters, and realized over 500 percent growth in the past five years. XYMOGEN's annual sales have skyrocketed from just over $5.2 million in 2004 to more than $68 million by the end of 2014.

"To really put things into perspective, our net sales for this one month were 30 percent larger than our entire first full year in 2004," Blackburn said. "While XYMOGEN has diversified its business model to include Contract Manufacturing and International Sales, the vast majority of growth came from growth in the North American Practitioner-Channel." 

XYMOGEN, who began selling their formulas internationally with Canada in 2012, now has product available in more than 16 different countries, across six continents. Blackburn believes the company's international growth is extremely important, as by reaching beyond the United States into international markets, XYMOGEN can achieve their ultimate goal to positively impact the health of people worldwide.  

"XYMOGEN was founded based upon what we felt were voids in the Practitioner-Channel of the nutracetutical industry," Blackburn said. "In particular, XYMOGEN focused on Exclusive and Patented Ingredients, Evidence-Based Dosing, and a strategy to eliminate the Internet sale of its professional formulas. XYMOGEN's ePedigree program has been highly successful with only 16 of its 230+ formulas available on the Internet as of January 31, 2015."  

The company began manufacturing their own formulas when they opened their new, 136,000-square-foot, state-of-the-art manufacturing facility and headquarters in 2012. Since that time, the facility has been GMP (Good Manufacturing Practices) and GMP for Sport registered with NSF International, one of the most respected independent product testing organizations. They also expect to be certified by the Australia Therapeutic Goods Association early in 2015.

To ensure future success, the company continues to improve their manufacturing capabilities and invest in practitioner education, international expansion and security initiatives, such as the aforementioned ePedigree track and trace program. These efforts, according to Blackburn, will allow the company to remain the fastest-growing company in the marketplace and guarantee that XYMOGEN's formulas are the most thoroughly researched and tested that the industry has to offer.

About XYMOGEN

XYMOGEN, a family-owned, health sciences company with headquarters in Orlando, Fla., has been providing high-quality dietary supplements to licensed health care practitioners for more than a quarter century.

The nutraceutical company has introduced numerous innovations to the functional medicine community; its Medical Board of Advisors consists of clinical practitioners who represent a broad range of specialties.

XYMOGEN's strength as a company was reinforced in 2007, 2008, 2010, 2011, 2012, 2013 and 2014 when it was recognized by Inc. Magazine as one of the 5,000 fastest-growing, best-run, most innovative and most inspiring private companies in America.

The company's 136,000-square-foot manufacturing facility is GMP (good manufacturing practices) and GMP for Sport Athletic Banned Substances Program registered by NSF International.

More information is available at www.xymogen.com. Please email [email protected] for comments or inquiries.

Distributed by Sara Brady Public Relations, Inc. 222 W. Comstock Avenue, Suite 215
Winter Park, Florida  32789 407-702-6632
www.sarabradypr.com

For information, contact:
Sara Brady
407-702-6632
[email protected]

SOURCE XYMOGEN